Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00939952 · ClinicalTrials.gov registry record · Phase 4
Ertapenem Pharmacokinetics in Patients in Continuous Ambulatory Peritoneal Dialysis
A Phase 4 study of End Stage Renal Disease and Continuous Ambulatory Peritoneal Dialysis, sponsored by Albany College of Pharmacy and Health Sciences.
- Completed
- Registry status
- Phase 4
- Development phase
- 7
- Enrollment target
- 1
- Study location
NCT00939952 is a Phase 4 study of End Stage Renal Disease and Continuous Ambulatory Peritoneal Dialysis that has completed, run by Albany College of Pharmacy and Health Sciences. The registered enrollment target is 7 participants, below the 833-participant average among 86 other End Stage Renal Disease trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00939952, a Phase 4 study of End Stage Renal Disease and Continuous Ambulatory Peritoneal Dialysis, has completed, sponsored by Albany College of Pharmacy and Health Sciences.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 7 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of this study is to characterize the pharmacokinetic profile of ertapenem during continuous ambulatory peritoneal dialysis (CAPD).
Conditions Studied
Interventions
- DRUG ertapenem
Study Locations (1)
New York
- Hortense and Louis Rubin Dialysis Center - Clifton Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2009-06 |
| Est. Completion | 2010-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00939952
The ClinicalTrials.gov registry entry for NCT00939952 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 833-participant average among 86 other End Stage Renal Disease trials with a reported enrollment target (99% lower). The listed sponsor is Albany College of Pharmacy and Health Sciences, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with End Stage Renal Disease appearing as the primary indexed condition, and to 1 intervention - of which ertapenem is the first listed.
NCT00939952 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT00939952 about?
NCT00939952 is a clinical study titled "Ertapenem Pharmacokinetics in Patients in Continuous Ambulatory Peritoneal Dialysis". The objective of this study is to characterize the pharmacokinetic profile of ertapenem during continuous ambulatory peritoneal dialysis (CAPD).
What is the current status of trial NCT00939952?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 7 participants. The study started on 2009-06. Estimated completion is 2010-05.
What conditions does trial NCT00939952 study?
This clinical trial studies the following conditions: End Stage Renal Disease, Continuous Ambulatory Peritoneal Dialysis.
What interventions are being tested in trial NCT00939952?
The interventions under investigation include: ertapenem (DRUG).
Who is sponsoring clinical trial NCT00939952?
This trial is sponsored by Albany College of Pharmacy and Health Sciences, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00939952 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for End Stage Renal Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Ferric Citrate in ESRD Pilot Project
ACTIVE NOT RECRUITING · Phase 4
-
One-month Latent Tuberculosis Treatment for Renal Transplant Candidates
ACTIVE NOT RECRUITING · Phase 4
-
Patiromer Efficacy to Reduce Episodic Hyperkalemia in End Stage Renal Disease Patients
COMPLETED · Phase 4
-
A Long-Term Study of Tenapanor Alone or in Combination With Sevelamer in Patients With CKD on Dialysis and HP
COMPLETED · Phase 4
-
Triferic AVNU Infusion Via Freedom Pump During Hemodialysis
COMPLETED · Phase 4
-
Thymoglobulin Versus Alemtuzumab Versus Daclizumab in Living Donor Renal Transplantation
COMPLETED · Phase 4
Explore more on PlainTrial
End Stage Renal Disease
All registered trials for this condition
Continuous Ambulatory Peritoneal Dialysis
All registered trials for this condition
New York
All trials with a study site in New York
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.